| Project/Area Number |
26253080
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
Konishi Ikuo 京都大学, 医学研究科, 名誉教授 (90192062)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
森 誠一 公益財団法人がん研究会, その他部局等, 研究員 (10334814)
岡本 愛光 東京慈恵会医科大学, 医学部, 教授 (20204026)
山口 建 京都大学, 医学(系)研究科(研究院), 助教 (20378772)
松村 謙臣 京都大学, 医学(系)研究科(研究院), 准教授 (20452336)
安彦 郁 京都大学, 医学(系)研究科(研究院), 助教 (20508246)
松田 文彦 京都大学, 医学(系)研究科(研究院), 教授 (50212220)
山田 亮 京都大学, 医学(系)研究科(研究院), 教授 (50301106)
馬場 長 京都大学, 医学(系)研究科(研究院), 講師 (60508240)
濱西 潤三 京都大学, 医学(系)研究科(研究院), 助教 (80378736)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥41,730,000 (Direct Cost: ¥32,100,000、Indirect Cost: ¥9,630,000)
Fiscal Year 2016: ¥11,960,000 (Direct Cost: ¥9,200,000、Indirect Cost: ¥2,760,000)
Fiscal Year 2015: ¥11,960,000 (Direct Cost: ¥9,200,000、Indirect Cost: ¥2,760,000)
Fiscal Year 2014: ¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
|
|---|
| Keywords | 卵巣癌 / 化学療法予測 / 個別化治療 / タキサン / 個別化 / 卵巣漿液性癌 / 卵巣明細胞癌 / 腫瘍免疫 / 上皮間葉転換 / 癌 / ゲノム / 卵巣明細胞腺癌 / バイオマーカー / 抗腫瘍免疫 / 分子標的療法 / 化学療法感受性 / アノイキス抵抗性 |
|---|
| Outline of Final Research Achievements |
Prognoses of ovarian cancer have improved with the paclitaxel-carboplatin regimen. However, it remains unclear which cases exhibit a genuine benefit from taxane or from platinum. We aimed to predict taxane and platinum sensitivity via gene expression. Recently, The Cancer Genome Atlas data revealed four molecular subtypes of high-grade serous ovarian carcinoma (HGSOC) exhibiting distinct prognoses. We developed four novel HGSOC histopathological subtypes by focusing on tumor microenvironment and unraveled its mechanism. We discovered that the Mesenchymal Transition type which represents the “Mesenchymal” gene expression subtype could respond better to a dose dense taxane combined with carboplatin (ddTC) rather than a conventional taxane and carboplatin (TC) treatment. This new pathological classification reflecting HGSOC gene expression subtypes leads to individualization of chemotherapy treatments.
|
